RETAIN BLADDER: a risk-adapted approach to muscle invasive bladder cancer

Daniel Geynisman, MD, Fox Chase Cancer Center, Philadelphia, PA, describes the interim analysis of the ongoing Phase II RETAIN BLADDER study, which aims to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer (MIBC). In this study, tumors from 71 patients with MIBC were sequenced for mutations, with the aim of identifying a specific subset of patients that could be spared cystectomy or chemoradiation following standard of care neoadjuvant chemotherapy, in order to improve quality of life while preserving oncologic outcomes in these patients. This interview took place during the 2021 Genitourinary Cancers Symposium.